Efficacy of Combination Therapy of Fluvoxamine and Favipiravir versus Favipiravir Monotherapy to Prevent Severe COVID-19 among Mild to Moderate COVID-19 Patients: Open-label Randomized Controlled Trial (EFFaCo Study)

DOI record: { "DOI": "10.1016/j.ijid.2023.06.018", "ISSN": [ "1201-9712" ], "URL": "http://dx.doi.org/10.1016/j.ijid.2023.06.018", "alternative-id": [ "S1201971223006410" ], "assertion": [ { "label": "This article is maintained by", "name": "publisher", "value": "Elsevier" }, { "label": "Article Title", "name": "articletitle", "value": "Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study)" }, { "label": "Journal Title", "name": "journaltitle", "value": "International Journal of Infectious Diseases" }, { "label": "CrossRef DOI link to publisher maintained version", "name": "articlelink", "value": "https://doi.org/10.1016/j.ijid.2023.06.018" }, { "label": "Content Type", "name": "content_type", "value": "article" }, { "label": "Copyright", "name": "copyright", "value": "© 2023 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases." } ], "author": [ { "ORCID": "http://orcid.org/0000-0001-7256-9982", "affiliation": [], "authenticated-orcid": false, "family": "Siripongboonsitti", "given": "Taweegrit", "sequence": "first" }, { "affiliation": [], "family": "Ungtrakul", "given": "Teerapat", "sequence": "additional" }, { "affiliation": [], "family": "Tawinprai", "given": "Kriangkrai", "sequence": "additional" }, { "affiliation": [], "family": "Nimmol", "given": "Tararin", "sequence": "additional" }, { "affiliation": [], "family": "Buttakosa", "given": "Mullika", "sequence": "additional" }, { "affiliation": [], "family": "Sornsamdang", "given": "Gaidganok", "sequence": "additional" }, { "affiliation": [], "family": "Jarrusrojwuttikul", "given": "Tanadul", "sequence": "additional" }, { "affiliation": [], "family": "Silapant", "given": "Phumin", "sequence": "additional" }, { "affiliation": [], "family": "Mahanonda", "given": "Nithi", "sequence": "additional" } ], "container-title": "International Journal of Infectious Diseases", "container-title-short": "International Journal of Infectious Diseases", "content-domain": { "crossmark-restriction": true, "domain": [ "clinicalkey.fr", "clinicalkey.jp", "clinicalkey.es", "clinicalkey.com.au", "clinicalkey.com", "ijidonline.com", "elsevier.com", "sciencedirect.com" ] }, "created": { "date-parts": [ [ 2023, 6, 30 ] ], "date-time": "2023-06-30T06:07:12Z", "timestamp": 1688105232000 }, "deposited": { "date-parts": [ [ 2023, 10, 13 ] ], "date-time": "2023-10-13T19:14:19Z", "timestamp": 1697224459000 }, "funder": [ { "DOI": "10.13039/100016175", "doi-asserted-by": "publisher", "name": "Chulabhorn Royal Academy" } ], "indexed": { "date-parts": [ [ 2024, 3, 26 ] ], "date-time": "2024-03-26T21:51:53Z", "timestamp": 1711489913784 }, "is-referenced-by-count": 5, "issued": { "date-parts": [ [ 2023, 9 ] ] }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2023, 9, 1 ] ], "date-time": "2023-09-01T00:00:00Z", "timestamp": 1693526400000 } }, { "URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2023, 6, 20 ] ], "date-time": "2023-06-20T00:00:00Z", "timestamp": 1687219200000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S1201971223006410?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S1201971223006410?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "page": "211-219", "prefix": "10.1016", "published": { "date-parts": [ [ 2023, 9 ] ] }, "published-print": { "date-parts": [ [ 2023, 9 ] ] }, "publisher": "Elsevier BV", "reference": [ { "DOI": "10.1056/NEJMoa2118542", "article-title": "Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19", "author": "Hammond", "doi-asserted-by": "crossref", "first-page": "1397", "journal-title": "N Engl J Med", "key": "10.1016/j.ijid.2023.06.018_bib0001", "volume": "386", "year": "2022" }, { "DOI": "10.1056/NEJMoa2116044", "article-title": "Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients", "author": "Jayk Bernal", "doi-asserted-by": "crossref", "first-page": "509", "journal-title": "N Engl J Med", "key": "10.1016/j.ijid.2023.06.018_bib0002", "volume": "386", "year": "2022" }, { "key": "10.1016/j.ijid.2023.06.018_bib0003", "unstructured": "United States Food and Drug Administration, FDA Network of European World Shops. RELEASE, coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19, https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19; 2021 [accessed 22 December 2021]." }, { "key": "10.1016/j.ijid.2023.06.018_sbref0004", "series-title": "Clinical practice guideline to diagnosis, treatment and prevention COVID-19 for Physicain and health care provider", "year": "2021" }, { "DOI": "10.1038/s41598-021-90551-6", "article-title": "Martinez-de-Hoyo R. The efficacy and safety of favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials", "author": "Hassanipour", "doi-asserted-by": "crossref", "first-page": "11022", "journal-title": "Sci Rep", "key": "10.1016/j.ijid.2023.06.018_bib0005", "volume": "11", "year": "2021" }, { "DOI": "10.1186/s12985-020-01412-z", "article-title": "Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis", "author": "Shrestha", "doi-asserted-by": "crossref", "first-page": "141", "journal-title": "Virol J", "key": "10.1016/j.ijid.2023.06.018_bib0006", "volume": "17", "year": "2020" }, { "DOI": "10.1093/cid/ciab962", "article-title": "Efficacy of early treatment with favipiravir on disease progression among high-risk patients with coronavirus disease 2019 (COVID-19): a randomized, open-label clinical trial", "author": "Chuah", "doi-asserted-by": "crossref", "first-page": "e432", "journal-title": "Clin Infect Dis", "key": "10.1016/j.ijid.2023.06.018_bib0007", "volume": "75", "year": "2022" }, { "DOI": "10.1002/cpt.1844", "article-title": "Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection", "author": "Du", "doi-asserted-by": "crossref", "first-page": "242", "journal-title": "Clin Pharmacol Ther", "key": "10.1016/j.ijid.2023.06.018_bib0008", "volume": "108", "year": "2020" }, { "DOI": "10.2183/pjab.93.027", "article-title": "Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase", "author": "Furuta", "doi-asserted-by": "crossref", "first-page": "449", "journal-title": "Proc Jpn Acad Ser B Phys Biol Sci", "key": "10.1016/j.ijid.2023.06.018_bib0009", "volume": "93", "year": "2017" }, { "article-title": "Experimental treatment with favipiravir for COVID-19: an open-label control study", "author": "Cai", "first-page": "1192", "journal-title": "Engineering (Beijing)", "key": "10.1016/j.ijid.2023.06.018_bib0010", "volume": "6", "year": "2020" }, { "article-title": "Favipiravir versus arbidol for clinical recovery rate in moderate and severe adult COVID-19 patients: a prospective, multicenter, open-label, randomized clinical trial", "author": "Chen", "journal-title": "Front Pharmacol", "key": "10.1016/j.ijid.2023.06.018_bib0011", "volume": "12", "year": "2021" }, { "DOI": "10.1093/cid/ciaa1176", "article-title": "AVIFAVIR for treatment of patients with moderate coronavirus disease 2019 (COVID-19): interim results of a Phase II/III multicenter randomized clinical trial", "author": "Ivashchenko", "doi-asserted-by": "crossref", "first-page": "531", "journal-title": "Clin Infect Dis", "key": "10.1016/j.ijid.2023.06.018_bib0012", "volume": "73", "year": "2021" }, { "DOI": "10.3389/fphar.2021.652688", "article-title": "Fluvoxamine: a review of its mechanism of action and its role in COVID-19", "author": "Sukhatme", "doi-asserted-by": "crossref", "journal-title": "Front Pharmacol", "key": "10.1016/j.ijid.2023.06.018_bib0013", "volume": "12", "year": "2021" }, { "DOI": "10.1016/j.ijantimicag.2020.106044", "article-title": "Widely available lysosome targeting agents should be considered as potential therapy for COVID-19", "author": "Homolak", "doi-asserted-by": "crossref", "journal-title": "Int J Antimicrob Agents", "key": "10.1016/j.ijid.2023.06.018_bib0014", "volume": "56", "year": "2020" }, { "DOI": "10.1016/j.virol.2019.05.002", "article-title": "The ER stress sensor IRE1 and MAP kinase ERK modulate autophagy induction in cells infected with coronavirus infectious bronchitis virus", "author": "Fung", "doi-asserted-by": "crossref", "first-page": "34", "journal-title": "Virology", "key": "10.1016/j.ijid.2023.06.018_bib0015", "volume": "533", "year": "2019" }, { "DOI": "10.2165/00129784-200303030-00001", "article-title": "Effect of selective serotonin reuptake inhibitors on platelet activation: can they prevent acute myocardial infarction?", "author": "Schlienger", "doi-asserted-by": "crossref", "first-page": "149", "journal-title": "Am J Cardiovasc Drugs", "key": "10.1016/j.ijid.2023.06.018_bib0016", "volume": "3", "year": "2003" }, { "DOI": "10.1001/jama.2020.22760", "article-title": "Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial", "author": "Lenze", "doi-asserted-by": "crossref", "first-page": "2292", "journal-title": "JAMA", "key": "10.1016/j.ijid.2023.06.018_bib0017", "volume": "324", "year": "2020" }, { "DOI": "10.4269/ajtmh.21-1310", "article-title": "Fluvoxamine for the early treatment of COVID-19: a meta-analysis of randomized clinical trials", "author": "Guo", "doi-asserted-by": "crossref", "first-page": "1315", "journal-title": "Am J Trop Med Hyg", "key": "10.1016/j.ijid.2023.06.018_bib0018", "volume": "106", "year": "2022" }, { "DOI": "10.1016/S2214-109X(21)00448-4", "article-title": "Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial", "author": "Reis", "doi-asserted-by": "crossref", "first-page": "e42", "journal-title": "Lancet Glob Health", "key": "10.1016/j.ijid.2023.06.018_bib0019", "volume": "10", "year": "2022" }, { "DOI": "10.7326/M22-3305", "article-title": "Oral fluvoxamine with inhaled budesonide for treatment of early-onset COVID-19: a randomized platform trial", "author": "Reis", "doi-asserted-by": "crossref", "first-page": "667", "journal-title": "Ann Intern Med", "key": "10.1016/j.ijid.2023.06.018_bib0020", "volume": "176", "year": "2023" }, { "DOI": "10.1093/ofid/ofab050", "article-title": "Prospective cohort of fluvoxamine for early treatment of coronavirus Disease 19", "author": "Seftel", "doi-asserted-by": "crossref", "first-page": "ofab050", "journal-title": "Open Forum Infect Dis", "key": "10.1016/j.ijid.2023.06.018_bib0021", "volume": "8", "year": "2021" }, { "DOI": "10.1093/ofid/ofac492.1881", "doi-asserted-by": "crossref", "key": "10.1016/j.ijid.2023.06.018_bib0022", "unstructured": "McCarthy MW, Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Felker GM, et al. Fluvoxamine for outpatient treatment of COVID-19: a decentralized, placebo-controlled, randomized, platform clinical trial. medRxiv. 01 November 2022. https://www.medrxiv.org/content/10.1101/2022.10.17.22281178 [accessed 2 November 2022]." }, { "DOI": "10.1056/NEJMoa2201662", "article-title": "Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19", "author": "Bramante", "doi-asserted-by": "crossref", "first-page": "599", "journal-title": "N Engl J Med", "key": "10.1016/j.ijid.2023.06.018_bib0023", "volume": "387", "year": "2022" }, { "DOI": "10.18071/isz.74.0389", "article-title": "Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: a retrospective case-control study", "author": "Németh", "doi-asserted-by": "crossref", "first-page": "389", "journal-title": "Ideggyogy Sz", "key": "10.1016/j.ijid.2023.06.018_bib0024", "volume": "74", "year": "2021" }, { "DOI": "10.1016/j.bpsgos.2021.12.007", "article-title": "Risk of death in individuals hospitalized for COVID-19 with and without psychiatric disorders: an observational multicenter study in France", "author": "Hoertel", "doi-asserted-by": "crossref", "first-page": "56", "journal-title": "Biol Psychiatry Glob Open Sci", "key": "10.1016/j.ijid.2023.06.018_bib0025", "volume": "3", "year": "2023" }, { "DOI": "10.1001/jamanetworkopen.2021.33090", "article-title": "Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants", "author": "Oskotsky", "doi-asserted-by": "crossref", "journal-title": "JAMA Netw Open", "key": "10.1016/j.ijid.2023.06.018_bib0026", "volume": "4", "year": "2021" }, { "DOI": "10.1001/jamanetworkopen.2022.6269", "article-title": "Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization: a systematic review and meta-analysis", "author": "Lee", "doi-asserted-by": "crossref", "journal-title": "JAMA Netw Open", "key": "10.1016/j.ijid.2023.06.018_bib0027", "volume": "5", "year": "2022" }, { "DOI": "10.3947/ic.2021.0142", "article-title": "Fluvoxamine treatment of patients with symptomatic COVID-19 in a community treatment center: a preliminary result of randomized controlled trial", "author": "Seo", "doi-asserted-by": "crossref", "first-page": "102", "journal-title": "Infect Chemother", "key": "10.1016/j.ijid.2023.06.018_bib0028", "volume": "54", "year": "2022" }, { "DOI": "10.1016/S1473-3099(21)00685-X", "article-title": "Increased risk of hospitalisation and death with the delta variant in the USA", "author": "Bast", "doi-asserted-by": "crossref", "first-page": "1629", "journal-title": "Lancet Infect Dis", "key": "10.1016/j.ijid.2023.06.018_bib0029", "volume": "21", "year": "2021" } ], "reference-count": 29, "references-count": 29, "relation": {}, "resource": { "primary": { "URL": "https://linkinghub.elsevier.com/retrieve/pii/S1201971223006410" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Infectious Diseases", "Microbiology (medical)", "General Medicine" ], "subtitle": [], "title": "Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study)", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy", "volume": "134" }